VE-Statin/EGFL7 Antibody (parsatuzumab) [DyLight 550]
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-28832R
Recombinant Monoclonal Antibody
Conjugate
Catalog #
Key Product Details
Species Reactivity
Human
Applications
ELISA, Flow Cytometry, Functional
Label
DyLight 550 (Excitation = 562 nm, Emission = 576 nm)
Antibody Source
Recombinant Monoclonal Human IgG1 Clone # parsatuzumab
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
EGFL7
Clonality
Monoclonal
Host
Human
Isotype
IgG1
Applications for VE-Statin/EGFL7 Antibody (parsatuzumab) [DyLight 550]
Application
Recommended Usage
ELISA
Optimal dilutions of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Functional
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A purified
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: VE-Statin
Long Name
Vascular Endothelial Statin/EGF-like Domain, Multiple 7
Alternate Names
EGFL7, MEGF7, NOTCH4-like protein, VEStatin, ZNEU1
Gene Symbol
EGFL7
Additional VE-Statin Products
Product Documents for VE-Statin/EGFL7 Antibody (parsatuzumab) [DyLight 550]
Product Specific Notices for VE-Statin/EGFL7 Antibody (parsatuzumab) [DyLight 550]
DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...